entertainment -WSS

entertainment

author：entertainment 2025-10-02 11:07:58 - browse：45

Adam's take main illustration — Molly Ferguson/STAT

The eye disease physician in charge of a committee that flagged a rare but severe side effect involving a newly approved drug from Apellis Pharmaceuticals has financial ties to a competing drugmaker. The conflict raises questions about his supervision of an emerging safety issue for patients and its impact on the financial health of Apellis.

Peter Kaiser, a retinal disease expert who runs the Cole Eye Institute at the Cleveland Clinic, failed to report consulting fees and stock ownership in Iveric Bio on a financial disclosure form maintained by the American Society of Retina Specialists, or ASRS. Iveric Bio is developing a treatment for geographic atrophy, a common, age-related cause of vision loss and the same indication for which the Apellis drug was approved.

The financial conflict, which was undisclosed until after Kaiser was contacted about it by STAT, is relevant because Kaiser also chairs a committee of the ASRS responsible for monitoring the safety of retina drugs and devices. On July 15, Kaiser’s committee sent a letter to member doctors, alerting them to reports of eye inflammation in people receiving injections of Syfovre, the treatment recently approved and launched by Apellis.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： NYC plans to house migrants on an island in the East River

WSS

The drug industry has found itself all alone in Washington

Moderna hits safety problems in bold bid to reinvent medicine

South Korea begins evacuating thousands of Scouts from coastal campsite as tropical storm nears

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

What it’s like to watch children die of measles

Appeals court upholds Josh Duggar's conviction for downloading child sex abuse images

entertainment

entertainment

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

United colonoscopy coverage change 'may cost lives,' doctors say

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

Supreme Court strikes down use of affirmative action

The UK government moves asylum

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Moderna hits safety problems in bold bid to reinvent medicine

Dobbs anniversary: the lost opportunity of abortion as health care

A deep dive into Applied Therapeutics’ data, and questions on Cassava

hotspot

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Arizona Democrat to raise extreme heat with Biden 1 year out from Senate primary

What it’s like to watch children die of measles

Biden will tout long

With psoriasis trial ahead, Alumis raises $259 million

A deep dive into Applied Therapeutics’ data, and questions on Cassava

hotspot

Wikipedia

focus

knowledge